News | Thrombectomy Devices | January 05, 2017

Global Thrombectomy Devices Market to Exceed $1 Million by 2022

Sedentary lifestyles, rise in geriatric population and demand for more minimally invasive treatments among factors driving market growth

global thrombectomy devices market, Allied Market Research report, 2022

January 5, 2017 — A new report published by Allied Market Research forecasts that the global thrombectomy devices market was valued at $982 million in 2016, and is expected to reach $1.389 million by 2022. This total will be supported by a compound annual growth rate (CAGR) of 5.9 percent during the forecast period 2014 to 2022. Mechanical thrombectomy would continue to be the preferred technology throughout the analysis period. North America dominated with around half of the market share in 2015 and is projected to maintain the lead throughout the forecast period.

High occurrences of acute myocardial infarction, peripheral artery disease, deep vein thrombosis, venous thromboembolism (VTE) and pulmonary embolism owing to sedentary and unhealthy lifestyles majorly drives the market growth, according to the report. VTE is most common in adults >60 years of age. In addition, better healthcare infrastructure and an increase in demand for minimally-invasive treatments; a rise in the geriatric population, which increases incidence of cardiovascular diseases; and technological advancements and innovations are the factors that nurture the growth of the thrombectomy devices market. Some of the restraints associated with the market are scarcity of trained professionals, lack of awareness and the complicated use of devices.

The disposable thrombectomy devices segment generated the highest revenue in 2015 and would continue to follow this trend throughout the analysis period.

Geographically, North America occupied a major market share in 2015, and is expected to continue leading during the analysis period. This was attributed to the sedentary and unhealthy lifestyle of the current generation, demand of better healthcare infrastructure, and increase in demand for minimally-invasive treatments and incidence of cardiovascular diseases. However, Asia-Pacific followed by LAMEA are expected to be the fastest growing regions, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of thrombus.

The thrombectomy devices market holds a substantial scope for growth globally. Recent innovations — which embed introduction of innovative ideas such as use of lasers, ultraviolet radiation and 3-D image generation — will provide better results to the physicians and allow them to work more efficiently. The upcoming trend in this market is the introduction of a technique that involves the combination of decompressive hemicraniectomy and endovascular thrombectomy to treat patients with cerebral venous thrombosis.

Among the other key findings were:

  • Neurovascular disorder is the major indication that uses thrombectomy devices for treatment; with over half of the total market share in 2015;
  • Peripheral and coronary diseases segments are projected to grow at a significant CAGR;
  • Reusable thrombectomy devices is projected to grow at a CAGR of 7.7 percent;
  • The U.S market for thrombectomy devices is projected to grow at a CAGR of 5 percent; and
  • The United States was the largest country market in 2015, and is projected to maintain its lead until 2022.

Key players have adopted mergers and acquisitions and product launch as their key strategies in the thrombectomy devices market. This is due to the growth in competition and continuous technological advancements. In July, 2016, Penumbra launched the ACE 68 Reperfusion Catheter for commercial use in the U.S. This catheter uses the latest tracking technology advancements available and delivers maximum aspiration power for extracting thrombus in stroke intervention. This product launch is expected to strengthen the product portfolio of Penumbra, a leading market player. The major market players profiled in this report include Boston Scientific Corp., Medtronic Plc, Teleflex Inc., Penumbra Inc., The Spectranetics Corp., AngioDynamics Inc., Terumo Corp., Johnson and Johnson Inc., Stryker Corp. and Vascular Solutions Inc.

For more information: www.alliedmarketresearch.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Overlay Init